

DOI: ((will be filled in by the editorial staff))

Novel Synthesis of 2-Aminothiazoles *via* Fe(III)-Iodine Catalyzed Hantzsch Type Condensation

Sankuviruthiyil M Ujwaldev,^[a] Nissy Ann Harry,^[a] Mohan Neetha,^[a] and Gopinathan Anilkumar^{*[a][b][c]}

^[a] School of Chemical Sciences

Mahatma Gandhi University

P D Hills P O, Kottayam, Kerala, India, 686560

anilgi1@yahoo.com

^[b] Advanced Molecular Materials Research Centre (AMMRC)

Mahatma Gandhi University,

P D Hills P O, Kottayam, Kerala, India, 686560

^[c] Institute for Integrated Programmes and Research in Basic Sciences (IIRBS)

Mahatma Gandhi University,

P D Hills P O, Kottayam, Kerala, India, 686560

Received: ((will be filled in by the editorial staff))

Abstract. A Novel iron-iodine catalyzed one pot synthesis of 2-aminothiazoles from methyl aryl ketones and thiourea is demonstrated. This protocol can be considered as a catalyzed version of the classical Hantzsch aminothiazole synthesis as it enables the *in situ* generation of α -iodoketones in the reaction medium using catalytic amount of iodine leading to Hantzsch condensation with thiourea. The supply of iodine for multiple catalytic cycles is ensured by using catalytic amounts of iron as it enables iodide to iodine oxidation. The generality of this protocol is also well established in this manuscript by synthesizing a variety of 2-aminothiazoles from different ketones and thiourea.

Keywords: aminothiazole; catalysis ; Hantzsch reaction ; iodine ; iron


1. Introduction

2-Aminothiazoles are very important heterocycles known for their wide spectrum of biological activities. Many drugs are available in the market nowadays containing aminothiazole core including potent CNS active agents. Some of the examples are Cefdinir (Anti-biotic),^[1] Famotidine (Histamine-2 blocker),^[2] Abafungin (Anti-microbial),^[3] Fanutizole (Anti-inflammatory),^[4] Pramipexole (Treatment of Parkinson's disease)^[5] etc. The known methods for the synthesis of these molecules include **i)** from acetophenone and thiourea mediated by strong oxidizing agents^[6] like Sulfuryl chloride, Sulfur trioxide, Nitric acid, Sulfur, halogen^[7] etc. **ii)** from α -diazoketone and thiourea^[8] **iii)** from primary amines and halo-thiocyanatoalkenes^[9] **iv)** from alkynes and thiourea^[10] **v)** from α -nitro epoxides and thiourea^[11] **vi)** from vinyl azides with thiocyanate^[12] etc. Hantzsch condensation^[13] is a well explored


methodology which involves reaction of thioamides with α -haloketones to afford aminothiazoles. It was first reported in 1887 (**Scheme 1a**) and later underwent many developments. The major modification was the use of ketone along with stoichiometric amounts of iodine instead of haloketones to afford aminothiazoles on reaction with thiourea *i. e.* Oxidative cyclocondensation^[14] (**Scheme 1b**). This protocol was superior over **Scheme 1a**, since α -haloketones were less commercially available and possess lachrymatory nature. Use of stoichiometric amounts of iodine often resulted in the formation of unwanted by-products leading to complex separation procedures. Our group's continued interest in developing transition metal catalyzed versions of classic name reactions^[15] made us investigate a similar scope in the case of Hantzsch reaction also. By using a catalytic amount of iron and iodine, we could develop a protocol that employs acetophenone and thiourea as the starting materials to afford 2-aminothiazoles (**Scheme 1c**). We propose that *via* repeated iron-iodine-involved catalytic cycles, *in situ* generation of α -iodoacetophenone from acetophenone could take place in the reaction mixture which would react with thiourea to afford the product. The protocol is very useful towards the synthesis of a variety of 2-aminothiazoles from 2-methylketones and thiourea under much milder conditions.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jhet.4166


a) Classical Hantzsch Condensation



b) Oxidative Cyclocondensation



c) Our work: Iron-Iodine catalyzed Hantzsch Thiazole Synthesis




Scheme 1. Scheme 1: a) Classical Hantzsch condensation between α -halo ketone and thioamide; b) Oxidative cyclocondensation using stoichiometric amounts of iodine c) Our modification leading to catalytic version of Hantzsch condensation.

Recently many green approaches were emerged in the area of Hantzsch reaction to afford 2-aminothiazoles.^[16] Our methodology will be a new addition to these protocols as it uses environmentally benign PEG-400 as the solvent along with iron/iodine catalytic system.

2. Result and Discussion


The optimization studies were began with a trial reaction involving acetophenone, **1a** (0.5 mmol) and thiourea **2a** (0.6 mmol) as the substrates. Ferric chloride hexahydrate and iodine were used as the catalysts. All the reagents were stirred at 110 °C in a sealed tube using CH₃CN as the solvent (**Scheme 2**). The progress of the reaction was monitored using TLC and the reaction mixture was quenched after 24 hours and extracted using ethyl acetate. The residue obtained after concentration of the solvent was purified using column chromatography (Hexane-EtOAc) to furnish the desired 4-phenylthiazol-2-amine in 28 % yield.



Scheme 2: Iron catalyzed Hantzsch-type reaction between acetophenone and thiourea.

Once the trial reaction was found proceeding in the desired way, further studies were carried out by varying the iron salt, iodine source, solvent, time, temperature and the catalyst loading (**Table 1**).

Table 1: Optimization studies



Sl No	Iron catalyst (mol%)	Iodide source (mol%)	Solvent	Tem p. (°C)	Time (h)	Yield (%) ^{a,b}
1	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	CH ₃ CN	110	24	28
2	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	CH ₃ CN	80	24	18
3	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	CH ₃ CN	130	24	traces
4	FeCl ₃ ·6H ₂ O (30 mol%)	KI (30 mol%)	CH ₃ CN	110	24	24
5	Fe(NO ₃) ₃ ·9H ₂ O (20 mol%)	I ₂ (20 mol%)	CH ₃ CN	110	24	traces
6	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	DME	110	24	25
7	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	THF	110	24	traces
8	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	DMF	110	24	30
9	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	DMSO	110	24	traces
10	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	^t BuOH	110	24	38
11	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	EtOH	110	24	traces
12	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	Toluene	110	24	traces
13	FeCl ₃ ·6H ₂ O (20 mol%)	I ₂ (20 mol%)	NMP	110	24	28

	mol%)					
14	FeCl ₃ . 6H ₂ O (20 mol%)	I ₂ (20 mol%)	PEG- 400	110	24	41
15	FeCl ₃ . 6H ₂ O (30 mol%)	I ₂ (30 mol%)	PEG- 400	110	24	58
16	FeCl ₃ . 6H ₂ O (30 mol%)	I ₂ (30 mol%)	CH ₃ CN	110	24	48
17	FeCl ₃ . 6H ₂ O (30 mol%)	I ₂ (30 mol%)	DMF	110	24	38
18	FeCl ₃ . 6H ₂ O (30 mol%)	I ₂ (30 mol%)	^t BuOH	110	24	38
19	FeCl ₃ . 6H ₂ O (30 mol%)	I ₂ (30 mol%)	H ₂ O	110	24	traces
20	FeCl ₃ . 6H ₂ O (50 mol%)	I ₂ (50 mol%)	PEG- 400	110	24	43
21	FeCl ₃ . 6H ₂ O (20 mol%)	I ₂ (30 mol%)	PEG- 400	110	24	40
22	FeCl ₃ . 6H ₂ O (30 mol%)	I ₂ (30 mol%)	PEG- 400	110	19	43
23	FeCl ₃ . 6H ₂ O (30 mol%)	I ₂ (30 mol%)	PEG- 400	110	30	56
24	FeCl ₃ Anhydro us (30 mol%)	I ₂ (30 mol%)	PEG- 400	110	24	53
25	Fe(OTf) ₂ (30 mol%)	I ₂ (30 mol%)	PEG- 400	110	24	42
26	-	I ₂ (30 mol%)	PEG- 400	110	24	35
27	FeCl ₃ . 6H ₂ O (30 mol%)	-	PEG- 400	110	24	traces
28	-	-	PEG- 400	110	24	nd

^a **Reaction Conditions:** **1a** (0.5 mmol), **2a** (0.6 mmol), Fe catalyst (20-50 mol%), Iodide source (20-50 mol%),

Solvent, 80-110 °C, 19-30 h; ^b Isolated yield. nd= not detected.

The first parameter we modified in comparison to the trial reaction (**Entry 1**) was the temperature by keeping all the other parameters the same. A decrease or an increase in the temperature was found to cause the yield to decrease or the amount of product become traces (**Entry 2&3**). The use of Fe(NO₃)₃.9H₂O instead of FeCl₃.6H₂O or KI instead of I₂ also didn't improve the yields (**Entry 4&5**). Influence of different solvents in the reaction was then examined. Solvents including tetrahydrofuran, dimethylsulfoxide and ethanol were ineffective (**Entry 7, 9&11**). Similar was the result in the case of toluene (**Entry 12**). NMP gave only 28% of the yield while ^tBuOH and PEG-400 gave improved yields of 38% and 41% respectively (**Entry 13, 10&14**). Upon increasing the quantities of both FeCl₃.6H₂O and I₂ from 20 mol% to 30 mol%, the yields got increased. In the case of acetonitrile, the yield was improved to 48% (**Entry 16**). Similarly PEG-400 has furnished 58% of the product and was found to be the best solvent among the all (**Entry 15**). Thus we have chosen PEG-400 as the solvent for the subsequent studies. A decrease in the duration of the reaction from 24 hours to 19 hours resulted in lowering of the yield (**Entry 22**). However, an increase of reaction time did not make any impact on the yield (**Entry 23**). A change in the catalytic loading from 30 mol% to 50 mol% resulted in the decrease of the yield (**Entry 20**). We also changed the [Fe]:I₂ ratio to 1:1.5, which offered a reduced yield of 40% (**Entry 21**). The catalytic activity of a ferrous salt was also tested to afford 42% of the product (**Entry 25**). When the reaction was carried out in the absence of iron the yield was only 35% (**Entry 26**). The use of iron as the sole catalyst only delivered traces of the product (**Entry 27**). From all these results, we have concluded **Entry 15** as the optimum condition and proceeded with the substrate scope studies.

The generality of this protocol was well studied later with a variety of ketones and thiourea. Electron withdrawing as well as electron donating groups were well tolerated under the reaction conditions (**Scheme 3**). Electronic nature of the substituents on the arylketones did not make any direct correlation with the yields. Among the halo ketones, 4-chloroacetophenone offered the highest yield (**Scheme 3, 3da**) whereas 4-iodoacetophenone afforded the lowest (**Scheme 3, 3ga**). In the case of heterocyclic ketone, the yield was very low (**Scheme 3, 3ma**). Cyclopentanone furnished 5,6-dihydro-4H-cyclopenta[*d*]thiazol-2-amine as the product, *albeit* in very low amounts (**Scheme 3, 3na**). N-Phenylthiourea (**Scheme 3, 3ab**) has provided only 16% of the product, presumably due to steric effects.

NMR (CDCl₃, 125 MHz) δ 167.2, 151.6, 137.7, 132.2, 129.4, 126.1, 102.3, 21.4; GC-MS (EI): m/z 190 (M⁺).

4-(*m*-Tolyl)thiazol-2-amine (3ca);^[17] Chemical Formula: C₁₀H₁₀N₂S; Appearance: White Solid; Yield: 39 mg (41%); MP: 84–86 °C (lit. 88–91 °C)^[17]; ¹H NMR (DMSO-d₆, 500 MHz) δ 8.71 (bs, 2H), 7.55 (s, 1H), 7.51 (d, *J* = 10.0 Hz, 1H), 7.29 (t, *J* = 7.5 Hz, 1H), 7.17 (d, *J* = 7.5 Hz, 1H), 7.13 (s, 1H), 2.29 (s, 3H); ¹³C NMR (DMSO-d₆, 125 MHz) δ 169.2, 139.6, 137.4, 128.9, 128.6, 128.0, 125.3, 121.9, 101.3, 20.1; GC-MS (EI): m/z 190 (M⁺).

4-(4-Chlorophenyl)thiazol-2-amine (3da);^[17] Chemical Formula: C₉H₇ClN₂S; Appearance: White Solid; Yield: 64 mg (61%); MP: 165–167 °C (lit. 161–162 °C)^[17]; FT-IR (neat): 3435, 3279, 3108, 2757, 1631, 1532, 1327, 1036, ¹H NMR (CDCl₃, 500 MHz) δ 7.71 (d, *J* = 8.5 Hz, 2H), 7.34 (d, *J* = 10.0 Hz, 2H), 6.71 (s, 1H), 5.05 (s, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 167.4, 150.4, 133.6, 133.3, 128.9, 127.4, 103.4; GC-MS (EI): m/z 210 (M⁺).

4-(3-Chlorophenyl)thiazol-2-amine (3ea);^[18] Chemical Formula: C₉H₇ClN₂S; Appearance: White Solid; Yield: 58 mg (55 %); MP: 128–130 °C (lit. 126–128 °C)^[18]; FT-IR (neat): 3310, 3127, 1632, 1517, 1337, 1050, ¹H NMR (CDCl₃, 500 MHz) δ 7.69 (s, 1H), 7.56 (d, *J* = 7.5 Hz, 1H), 7.23–7.17 (m, 2H), 6.66 (s, 1H), 5.20 (s, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 167.6, 150.0, 136.5, 134.7, 130.0, 127.8, 126.3, 124.1, 104.0; GC-MS (EI): m/z 210 (M⁺).

4-(2,4-Dichlorophenyl)thiazol-2-amine (3fa);^[19] Chemical Formula: C₉H₆Cl₂N₂S; Appearance: White Solid; Yield: 61 mg (50%); MP: 157–159 °C (lit. 161–163 °C)^[19]; FT-IR (neat): 3451, 3275, 3107, 1630, 1536, 1335, 1025, ¹H NMR (CDCl₃, 500 MHz) δ 7.81 (d, *J* = 10.0 Hz, 1H), 7.45 (d, *J* = 2.0 Hz, 1H), 7.27 (dd, *J*₁ = 8.5 Hz, *J*₂ = 2.0 Hz, 1H), 7.08 (s, 1H), 5.02 (s, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 166.2, 146.6, 133.7, 132.5, 132.2, 132.0, 130.3, 127.3, 108.8; GC-MS (EI): m/z 244 (M⁺).

4-(4-Iodophenyl)thiazol-2-amine (3ga);^[18] Chemical Formula: C₉H₇IN₂S; Appearance: Pale Yellow Solid; Yield: 73 mg (48 %); MP: 167–169 °C (lit. 176–177 °C)^[18]; FT-IR (neat): 3420, 3279, 3107, 1627, 1530, 1326, 1034, ¹H NMR (CDCl₃, 500 MHz) δ 7.70 (d, *J* = 8.5 Hz, 2H), 7.52 (d, *J* = 8.5 Hz, 2H), 6.74 (s, 1H), 5.01 (s, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 167.4, 150.4, 137.8, 134.2, 127.9, 103.6, 93.3; GC-MS (EI): m/z 302 (M⁺).

4-(4-Bromophenyl)thiazol-2-amine (3ha);^[18] Chemical Formula: C₉H₇BrN₂S; Appearance: Pale Yellow Solid; Yield: 61 mg (48%); MP: 184–186 °C (lit. 179–181 °C)^[18]; FT-IR (neat): 3426, 3279, 3109, 2757, 1634, 1531, 1334, 1035, ¹H NMR (CDCl₃, 500 MHz) δ 7.65 (d, *J* = 8.5 Hz, 2H), 7.49 (d, *J* = 8.0 Hz, 2H), 6.73 (s, 1H), 5.02 (s, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 167.4, 150.4, 133.8, 131.8, 127.7, 121.8, 103.5; GC-MS (EI): m/z 254 (M⁺).

4-(4-Fluorophenyl)thiazol-2-amine (3ia);^[18] Chemical Formula: C₉H₇FN₂S; Appearance: White Solid; Yield: 53 mg (55%); MP: 100–102 °C (lit. 103–104 °C)^[18]; FT-IR (neat): 3469, 3306, 3126, 2767, 1639, 1533, 1338, 1037, ¹H NMR (CDCl₃, 500 MHz) δ 7.76–7.73 (m, 2H), 7.08–7.04 (m, 2H), 6.65 (s, 1H), 5.02 (s, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 167.3, 163.6, 161.6, 150.5, 140.1, 131.1 (2 peaks), 127.9, 127.8, 115.7, 115.5, 102.6 (2 peaks); GC-MS (EI): m/z 194 (M⁺).

4-(3-(Trifluoromethyl)phenyl)thiazol-2-amine (3ja);^[20] Chemical Formula: C₁₀H₇F₃N₂S; Appearance: White Solid; Yield: 40 mg (33%); MP: 103–105 °C; ¹H NMR (DMSO-d₆, 500 MHz) δ 8.13 (s, 1H), 8.09 (bs, 1H), 7.59 (bs, 2H), 7.25 (bs, 1H), 7.18 (s, 2H); ¹³C NMR (DMSO-d₆, 125 MHz) δ 167.7, 147.2, 134.9, 130.2, 130.1, 130.0, 129.7, 129.6, 129.5, 128.0, 125.8, 124.0 (2 peaks), 123.7, 122.4 (2 peaks), 121.5; GC-MS (EI): m/z 244 (M⁺).

4-(4-Nitrophenyl)thiazol-2-amine (3ka);^[17] Chemical Formula: C₉H₇N₃O₂S; Appearance: Yellow powder; Yield: 40 mg (36 %); MP: 284–286 °C (lit. 285–286 °C)^[17]; FT-IR (neat): 3394, 3302, 3145, 3114, 1638, 1592, 1536, 1410, 1317, 1036, ¹H NMR (DMSO-d₆, 400 MHz) δ 8.23 (d, *J* = 8.0 Hz, 2H), 8.04 (d, *J* = 8.0 Hz, 2H), 7.40 (s, 1H), 7.25 (s, 2H); ¹³C NMR (DMSO-d₆, 100 MHz) δ 168.6, 147.6, 146.0, 140.7, 126.3, 124.0, 106.6; GC-MS (EI): m/z 222 (M+H⁺).

4-(4-(Methylsulfonyl)phenyl)thiazol-2-amine (3la);^[21] Chemical Formula: C₁₀H₁₀N₂O₂S₂; Appearance: White powder; Yield: 65 mg (51 %); MP: 225–227 °C; FT-IR (neat): 3417, 3278, 3108, 1646, 1532, 1280, 1035, ¹H NMR (DMSO-d₆, 400 MHz) δ 8.04 (d, *J* = 8.0 Hz, 2H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.30 (s, 1H), 7.18 (s, 2H), 3.22 (s, 3H); ¹³C NMR (DMSO-d₆, 100 MHz) δ 168.5, 148.2, 139.4, 138.8, 127.4, 126.0, 105.2, 43.6; MS-MS (EI): m/z 255 (M+H⁺).

4-(Furan-2-yl)thiazol-2-amine (3ma);^[22] Chemical Formula: C₇H₆N₂OS; Appearance: White Solid; Yield: 20 mg (24%); MP: 112–114 °C (lit. 115 °C)^[23]; ¹H NMR (CDCl₃, 500 MHz) δ 7.39 (s, 1H), 6.69 (s, 1H), 6.62 (d, *J* = 3.5 Hz, 1H), 6.44 (m, 1H), 5.03 (s, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 167.6, 150.4, 143.0, 142.0, 111.5, 106.5, 102.5; GC-MS (EI): m/z 166 (M⁺).

N,4-Diphenylthiazol-2-amine (3ab);^[24] Chemical Formula: C₁₅H₁₂N₂S; Appearance: Slightly yellow Solid; Yield: 20 mg (16 %); MP: 138–140 °C (lit. 133–135 °C)^[25]; ¹H NMR (CDCl₃, 500 MHz) δ 7.86 (d, *J* = 10.0 Hz, 2H), 7.42–7.30 (m, 8H), 7.08 (t, *J* = 7.0 Hz, 2H), 6.84 (s, 1H); ¹³C NMR (CDCl₃, 125 MHz) δ 164.5, 151.5, 140.4, 134.7, 129.6, 128.8, 128.0, 126.2, 123.1, 118.3, 102.0; GC-MS (EI): m/z 252 (M⁺).

Acknowledgements

SMU and NAH thank the University Grants Commission (UGC-New Delhi), India and the Council of Scientific and Industrial Research (CSIR-New Delhi), India for Junior Research Fellowships respectively. GA and NM thank the Kerala State Council for Science Technology and Environment (KSCSTE), Trivandrum, India for a research grant (Order No. 341/2013/KSCSTE dated 15.03.2013) and a research fellowship respectively. The authors are also thankful to EVONIK Industries, Germany for financial support (ECRP 2016 dated 6.10.2016). We also thank the Sophisticated Analytical Instrument Facility (SAIF) Mahatma Gandhi University, Kottayam for MS-MS analysis.

References

- [1] P. D. R. Guay, *Clin Ther.* **2002**, *24*, 473–489.
- [2] L. Laine, A. J. Kivitz, A. E. Bello, A. Y. Grahn, A. Y. Schiff, A. S. Taha, *Am. J. Gastro.* **2012**, *107*, 379–386.
- [3] C. Borelli, M. Schaller, M. Niewerth, K. Nocker, B. Baasner, D. Berg, R. Tiemann, K. Tietjen, B. Fugmann, S. Lang-Fugmann, H. C. Korting, *Chemotherapy* **2008**, *54*, 245–259.
- [4] J. Pastre, D. L. Browne, M. O'Brien, S. V. Ley, *Org Proc Res Dev.* **2013**, *17*, 1183–1191.
- [5] C. De Battista, H. B. Solvason, J. A. Breen, A. F. Schatzberg, *J. Clin. Psychopharmacol.* **2000**, *20*, 274–275.
- [6] R. M. Dodson, L. C. King, *J. Am. Chem. Soc.* **1946**, *68*, 871–871.

- [7]. a) R. M. Dodson, L. C. King, *J. Am. Chem. Soc.* **1945**, *67*, 2242–2243. b) L. C. King, R. J. Hlavacek, *J. Am. Chem. Soc.* **1950**, *72*, 3722–3725.
- [8]. L. C. King, F. Miller, *J. Am. Chem. Soc.* **1949**, *71*, 367–368.
- [9]. M. Giffard, J. Cousseau, *Tetrahedron Lett.* **1983**, *24*, 5085–5088.
- [10] B. Madhav, S. N. Murthy, B.S.P. Anil Kumar, K. Ramesh, Y.V.D. Nageswar, *Tetrahedron Lett.* **2012**, *53*, 3835–3838.
- [11] D. Zhao, S. Guo, X. Guo, G. Zhang, Y. Yu, *Tetrahedron* **2016**, *72*, 5285–5289.
- [12] B. Chen, S. Guo, X. Guo, G. Zhang, Y. Yu, *Org Lett.* **2015**, *17*, 4698–4701.
- [13]. a) A. Hantzsch, J. H. Weber, *Ber. Dtsch. Chem. Ges.* **1887**, *20*, 3118–3132. b) G. W. Kabalka, A. R. Mereddy, *Tetrahedron Lett.* **2006**, *47*, 5171–5172. c) M. M. Heravi, P. Nargess, Y. S. Beheshtiha, B. Baghernejad, *Synth. Commun.* **2011**, *41*, 579–582. d) M. Kidwai, D. Bhatnagar, P. Mothsra, A. K. Singh, S. Dey, *J. Sulfur. Chem.* **2009**, *30*, 29–36.
- [14]. a) T. M. Potewar, S. A. Ingale, K. V. Srinivasan, *Tetrahedron* **2008**, *64*, 5019–5022. b) N. Narender, M. S. Reddy, V. P. Kumar, V. P. Reddy, Y. V. D. Nageswar, K. R. Rao, *J. Org. Chem.* **2007**, *72*, 1849–1851. c) H. Bouherrou, A. Saidoun, A. Abderrahmani, L. Abdellaziz, Y. Rachedi, F. Dumas, A. Demenceau, *Molecules* **2017**, *22*, 757–759. d) Y. -P. Zhu, J. -J. Yuan, Q. Zhao, M. Lian, Q. -H. Gao, M. -C. Liu, Y. Yang, A. -X. Wu, *Tetrahedron* **2012**, *68*, 173–178.
- [15]. S. M. Ujwaldev, K. R. Rohit, N. A. Harry, G. Anilkumar, *Tetrahedron Lett.* **2019**, *60*, 150950–150954.
- [16] a) D. C. Castillo, R. M. Carballo, J. A. Tzec-Interián, G. J. Mena-Rejón, *Tetrahedron Lett.* **2012**, *53*, 3934–3936. b) J. Safari, Z. A. -Jazini, Z. Zarnegar, M. Sadeghi, *Catal. Commun.* **2016**, *77*, 108–112.
- [17] J. Safari, M. Sadeghi, *Monatsh Chem.* **2017**, *148*, 745–749.
- [18]. M. Chunhua, Y. Miao, M. Zhao, P. Wu, J. Zhou, Z. Li, X. Xie, W. Zhang, *Tetrahedron* **2018**, *74*, 3602–3607.
- [19]. D. Zhu, J. Chen, H. Xiao, M. Liu, J. Ding, H. Wu, *Synth. Commun.* **2009**, *39*, 2895–2906.
- [20]. K. Ran, C. Gao, H. Deng, Q. Lei, X. You, N. Wang, Y. Shi, Z. Liu, W. Wei, C. Peng, L. Xiong, K. Xiao, L. Yu, *Bioorg. Med. Chem.* **2016**, *26*, 3669–3674.
- [21]. G. W. Kabalka, R. M. Arjun, *Tetrahedron Lett.* **2006**, *47*, 5171–5172.
- [22]. P. Z. Yan, Y. P. Zhu, J. J. Yuan, Q. Zhao, M. Lian, Q. H. Gao, M. C. Liu, Y. Yang, A. X. Wu, *Tetrahedron* **2012**, *68*, 173–178.
- [23]. S. P. Singh, R. Naithani, R. Aggarwal, Om Prakash, *Synth. Commun.* **1998**, *28*, 2371–2378.
- [24]. A. Mishra, M. Srivastava, P. Rai, S. Yadav, B. P. Tripathi, J. Singh, J. Singh, *RSC Adv.* **2016**, *6*, 49164–49172.

COMMUNICATION

Novel Synthesis of 2-Aminothiazoles via Fe(III)-Iodine Catalyzed Hantzsch Type Condensation

J. Heterocyclic Chem. **Year**, *Volume*, Page – Page

Sankuviruthiyil M Ujwaldev, Nissy Ann Harry, Mohan Neetha and Gopinathan Anilkumar*

